Perioperative medicine & outcomes
Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial
Primary result · GI-2 (composite of time to first stool and tolerance of oral diet)Result — go to the resultDifference 1 day shorterAuthors' conclusion
Pyridostigmine resulted in a quicker return of GI-2 and was well tolerated.
Study context
- Population
- Adults undergoing elective colorectal surgery at two hospitals in South Australia
- Participants
- 130 adults
- Comparison
- Oral pyridostigmine 60 mg twice daily vs placebo
- Pyridostigminen = 65
- Placebon = 65reference
- Primary endpoint
- GI-2 (validated composite of time to first stool and tolerance of oral diet)
Methodological detailsdouble-blinded, placebo-controlled, two hospitals
- Double-blinded
- Placebo-controlled
- Two hospitals
Primary result
As reported in the abstract
GI-2:
- Time to first stool
- Tolerance of oral diet
Difference
1 day shorter
P = 0.015
Secondary outcomes
| Outcome | P value |
|---|---|
| Postoperative ileus (GI-2 >4 days)No significant difference · ITT analysis | P = 0.532 |
| Hospital LOSNo significant difference · ITT analysis | P = 0.921 |
Safety
Overall complications, anastomotic leak, cardiac complications, patient-reported side effects
- No significant differences between groups
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Pyridostigmine to Reduce the duration of postoperative Ileus after Colorectal surgery (PyRICo-RCT): randomized clinical trial. Br J Surg. Published 14 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →